摘要
目的探讨注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(recombinant human type II tumor necrosis factor receptor-antibody fusion protein,rhTNFR:Fc)联合沙利度胺对强直性脊柱炎(ankylosing spondylitis,AS)患者血清炎性因子的影响。方法选取2016年3月~2018年10月经本院诊治的AS患者82例,随机分为研究组和对照组各41例。对照组患者给予沙利度胺口服治疗,研究组患者在对照组的基础上加用rhTNFR:Fc皮下注射治疗,两组均持续治疗12周。比较两组患者治疗前及治疗后6周、12周的血清红细胞沉降率(erythrocyte sedimentation rate,ESR)、C反应蛋白(C-reactive protein,CRP)及肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)水平及临床症状。记录两组患者临床疗效及不良反应发生情况。结果研究组患者临床总有效率为95.12%,明显高于对照组的80.49%(P <0.05);治疗后6周、12周,两组患者ESR、CRP、TNF-α水平均明显低于治疗前,但研究组三项指标水平均明显低于对照组(P <0.05);治疗后6周、12周,两组患者临床各指标均较治疗前明显改善,但研究组患者临床各指标改善效果明显优于对照组(P <0.05);两组患者并发症发生率的比较,无统计学差异(P >0.05)。结论rhTNFR:Fc联合沙利度胺可明显改善机体炎症反应,有效缓解临床症状,具有显著疗效。
Objective To investigate the effect of recombinant human type II tumor necrosis factor receptor-antibody fusion protein(rhTNFR:Fc)combined with thalidomide for injection on serum inflammatory factors in patients with ankylosing spondylitis(AS).Methods Eighty-two patients with AS who were treated in our hospital from March 2016 to October 2018 were enrolled.According to the random number table method,the study group and the control group were divided into 41 cases.The patients in the control group were treated with thalidomide orally.The patients in the study group were treated with subcutaneous injection of rhTNFR:Fc on the basis of the control group.Both groups continued treatment for 12 weeks.The serum erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)levels and clinical symptoms were compared between 6 weeks and 12 weeks before and after treatment.The clinical efficacy and adverse reactions of the two groups were recorded.Results The total clinical effective rate of the study group was 95.12%,which was significantly higher than that of the control group’80.49%(P<0.05);at 6 weeks and 12 weeks after treatment,the levels of serum ESR、CRP and TNF-αin the two groups were significantly lower than those before treatment,but the serum ESR、CRP and TNF-αlevels in the study group were significantly lower than those in the control group(P<0.05);after 6 weeks and 12 weeks treatment,the clinical indexes of the two groups were significantly improved compared with those before treatment,but the improvement effect of clinical indicators in the study group was significantly better than that of the control group(P<0.05);there was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion rhTNFR:Fc combined with thalidomide can significantly improve the body's inflammatory response,effectively alleviate clinical symptoms,and the curative effect is remarkable.
作者
李晓龙
苏振炎
张益宏
姬健钧
LI Xiao-long;SU Zhen-yan;ZHANG Yi-hong;JI Jian-jun(The Second Department of Orthopaedics,Kaifeng Central Hospital,Kai feng,Henan,475000,China)
出处
《颈腰痛杂志》
2020年第3期321-324,共4页
The Journal of Cervicodynia and Lumbodynia
基金
宁夏回族自治区自然科学基金(编号:NZ16212)。
关键词
注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
沙利度胺
强直性脊柱炎
炎性因子
疗效
recombinant human type II tumor necrosis factor receptor-antibody fusion protein for injection
thalidomide
ankylosing spondylitis
inflammatory factor
therapeutic effect
